Insulin icodec
Ultralong-acting basal insulin analogue
From Wikipedia, the free encyclopedia
Insulin icodec, sold under the brand name Awiqli, is an anti-diabetic medication.[3] It is given once per week and its benefits are similar to long-acting daily insulin.[9]
| Clinical data | |
|---|---|
| Trade names | Awiqli |
| Other names | insulin icodec-abae |
| AHFS/Drugs.com | awiqli |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C280H435N71O87S6 |
| Molar mass | 6380.33 g·mol−1 |
It is an ultralong-acting basal insulin analogue that is developed by Novo Nordisk.[3] It has a plasma half-life more than eight days[10] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.[10]
Insulin icodec was approved for medical use in the United States in March 2026.[11]
Medical uses
Insulin icodec is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Pharmacology
Like insulin, icodec is composed of two peptide chains linked by a disulfide bridge. However, a C20 fatty diacid-containing side chain has been added for strong, reversible albumin binding; and three amino acid substitutions provide molecular stability and attenuate insulin receptor binding and clearance. Together, these modifications prolong the half-life.[12]
Society and culture
Legal status
Insulin icodec was approved for medical use in Canada in March 2024.[3]
In March 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Awiqli, intended for the treatment of diabetes.[7] The applicant for this medicinal product is Novo Nordisk A/S.[7] Insulin icodec was authorized for medical use in the European Union in May 2024.[8]
Names
Insulin icodec is the international nonproprietary name.[13]
Research
Based on a clinical trial, glycemic control was found to be non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100.[14]
